Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation.
ACTIVE
ARISTOTLE
AVERROES
Angiopoietin-2
Atrial fibrillation
Heart failure
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
04 07 2023
04 07 2023
Historique:
received:
04
05
2023
accepted:
24
05
2023
medline:
23
10
2023
pubmed:
18
7
2023
entrez:
18
7
2023
Statut:
ppublish
Résumé
Several biomarkers are associated with clinical outcomes in patients with atrial fibrillation (AF), but a causal relationship has not been established. This study aimed to evaluate angiopoietin-2, a novel candidate biomarker of endothelial inflammation and vascular remodelling, in patients with AF. Angiopoietin-2 was measured in plasma obtained from patients with AF treated with aspirin monotherapy (exploration cohort, n = 2987) or with oral anticoagulation (validation cohort, n = 13 079). Regression models were built to assess the associations between angiopoietin-2, clinical characteristics, and outcomes. In both cohorts, plasma angiopoietin-2 was independently associated with AF on the baseline electrocardiogram and persistent/permanent AF, age, history of heart failure, female sex, tobacco use/smoking, body mass index, renal dysfunction, diabetes, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Angiopoietin-2 was independently associated with subsequent hospitalization for heart failure after adjusting for age, creatinine, and clinical characteristics in the exploration cohort [c-index 0.79, 95% confidence interval (CI) 0.75-0.82; third vs. first quartile, hazard ratio (HR) 1.74, 95% CI 1.26-2.41] and in the validation cohort (c-index 0.76, 95% CI 0.74-0.78; HR 1.58, 95% CI 1.37-1.82). In both cohorts, the association persisted when also adjusting for NT-proBNP (P ≤ 0.001). In full multivariable models also adjusted for NT-proBNP, angiopoietin-2 did not show statistically significant associations with ischaemic stroke, cardiovascular and all-cause death, or major bleeding that were consistent across the two cohorts. In patients with AF, plasma levels of angiopoietin-2 were independently associated with subsequent hospitalization for heart failure and provided incremental prognostic value to clinical risk factors and NT-proBNP.
Identifiants
pubmed: 37461214
pii: 7225558
doi: 10.1093/europace/euad200
pmc: PMC10359110
pii:
doi:
Substances chimiques
Angiopoietin-2
0
Biomarkers
0
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanofi-Aventis and Bristol-Myers Squibb
Organisme : Bristol-Myers Squibb and Pfize
Organisme : Roche Diagnostics
Organisme : Bristol-Myers Squibb and Pfizer
Organisme : Swedish Society for Medical Research
ID : S17-0133
Organisme : Swedish Heart-Lung Foundation
ID : 20200722
Organisme : Uppsala University Hospital
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Thromb Haemost. 2018 Apr;118(4):791-797
pubmed: 29618157
Nat Med. 2006 Feb;12(2):235-9
pubmed: 16462802
Circulation. 2003 Jul 22;108(3):275-81
pubmed: 12847065
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
J Am Heart Assoc. 2021 Apr 20;10(8):e019168
pubmed: 33843247
Circulation. 2021 May 11;143(19):1863-1873
pubmed: 33849281
Blood. 2004 Jun 1;103(11):4150-6
pubmed: 14976056
Nat Rev Cardiol. 2023 Mar;20(3):145-167
pubmed: 36109633
Ann Med. 2008;40(3):215-22
pubmed: 18382887
Circulation. 2014 Feb 11;129(6):625-34
pubmed: 24226808
Eye (Lond). 2021 May;35(5):1305-1316
pubmed: 33564135
Crit Care. 2010;14(3):R89
pubmed: 20482750
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9355-8
pubmed: 8415706
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a006550
pubmed: 22951441
Circulation. 2020 Oct 13;142(15):1408-1421
pubmed: 32885678
Lancet. 2016 Sep 17;388(10050):1161-9
pubmed: 27515684
BMC Cardiovasc Disord. 2011 Jun 14;11:31
pubmed: 21672190
Science. 1997 Jul 4;277(5322):55-60
pubmed: 9204896
Eur Heart J. 2018 Feb 7;39(6):477-485
pubmed: 29069359
Circulation. 2019 Mar 5;139(10):1289-1299
pubmed: 30586730
J Thromb Haemost. 2012 Aug;10(8):1500-7
pubmed: 22681487
Europace. 2020 Oct 1;22(10):1463-1469
pubmed: 32830215
Am Heart J. 2017 Aug;190:94-103
pubmed: 28760218
Hum Mol Genet. 2016 Apr 1;25(7):1447-56
pubmed: 26908625
Circ Res. 2020 Sep 25;127(8):1036-1055
pubmed: 32762493
N Engl J Med. 2011 Mar 3;364(9):806-17
pubmed: 21309657
J Am Heart Assoc. 2020 Dec 15;9(24):e018984
pubmed: 33292046
J Thromb Haemost. 2021 Nov;19(11):2726-2737
pubmed: 34390530
Am Heart J. 2022 Sep;251:13-24
pubmed: 35569564
N Engl J Med. 2005 Feb 17;352(7):666-75
pubmed: 15716560
J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84
pubmed: 23563134
Thorax. 2008 Oct;63(10):903-9
pubmed: 18559364
J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61
pubmed: 24055845
Circulation. 2013 Nov 12;128(20):2192-201
pubmed: 24016454
Circulation. 2016 Nov 29;134(22):1697-1707
pubmed: 27569438
Lancet. 2016 Jun 4;387(10035):2302-2311
pubmed: 27056738
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
PLoS One. 2015 Aug 14;10(8):e0135181
pubmed: 26274392
Am J Cardiol. 2012 Jan 1;109(1):95-9
pubmed: 21962993
J Am Coll Cardiol. 2019 May 7;73(17):2195-2205
pubmed: 31047008
Circulation. 2014 Nov 18;130(21):1847-58
pubmed: 25294786
Am Heart J. 2015 Dec;170(6):1151-60
pubmed: 26678637
Eur Heart J. 2016 May 21;37(20):1582-90
pubmed: 26920728
N Engl J Med. 2009 May 14;360(20):2066-78
pubmed: 19336502
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77
pubmed: 19234476
Int J Cardiol. 2013 Aug 20;167(4):1159-63
pubmed: 22483260
Eur J Heart Fail. 2013 Dec;15(12):1327-34
pubmed: 23901057
Cardiovasc Res. 2022 Jul 20;118(9):2112-2123
pubmed: 34358298
Cells. 2019 May 17;8(5):
pubmed: 31108880
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607